Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, April 2001, p. 1109-1114, Vol. 45, No. 4
0066-4804/01/$04.00+0 DOI: 10.1128/AAC.45.4.1109-1114.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Mdt(A), a New Efflux Protein Conferring Multiple
Antibiotic Resistance in Lactococcus lactis and
Escherichia coli
Vincent
Perreten,1,2,3
Franziska V.
Schwarz,3
Michael
Teuber,3 and
Stuart B.
Levy1,2,4,*
Center for Adaptation Genetics and Drug
Resistance1 and Departments of Molecular
Biology and Microbiology2 and of
Medicine,4 Tufts University School of Medicine,
Boston, Massachusetts 02111, and Laboratory of Food
Microbiology, Institute of Food Science, Department of Agriculture and
Food Science, Eidgenössische Technische Hochschule Zürich,
ETH-Zentrum, CH-8092 Zürich, Switzerland3
Received 8 August 2000/Returned for modification 12 November
2000/Accepted 12 January 2001
 |
ABSTRACT |
The mdt(A) gene, previously designated
mef214, from Lactococcus lactis subsp.
lactis plasmid pK214 encodes a protein [Mdt(A) (multiple
drug transporter)] with 12 putative transmembrane segments (TMS) that
contain typical motifs conserved among the efflux proteins of the major
facilitator superfamily. However, it also has two C-motifs (conserved
in the fifth TMS of the antiporters) and a putative ATP-binding site.
Expression of the cloned mdt(A) gene decreased
susceptibility to macrolides, lincosamides, streptogramins, and
tetracyclines in L. lactis and Escherichia
coli, but not in Enterococcus faecalis or in
Staphylococcus aureus. Glucose-dependent efflux of
erythromycin and tetracycline was demonstrated in L. lactis
and in E. coli.
 |
INTRODUCTION |
Lactococci are important lactic acid
bacteria used in the process of preparing fermented dairy products.
Naturally found on plants and on parts of the body of cows, these
bacteria are widely used as a starter culture in the dairy industry
(37). Antibiotics used in animal husbandry have selected
for antibiotic-resistant flora (44). Such resistant
bacteria may contaminate milk and meat and persist in food made from
their raw materials. Indeed, Lactococcus lactis subsp.
lactis K214 isolated from a raw milk soft cheese has been
shown to harbor a multiple antibiotic resistance plasmid
(30). This plasmid, pK214, carries genes for
chloramphenicol acetyltransferase (cat) and streptomycin
adenylase (str), a tetracycline resistance gene
[tet(S)], and a putative drug efflux gene previously named
mef214 (30, 38).
Efflux proteins, membrane proteins distributed among gram-positive and
gram-negative bacteria, are involved in transmembrane export of
different substances such as heavy metals, organic solvents, dyes,
disinfectants, and antibiotics (21, 22, 26, 35). Some
efflux proteins are specific to a single class of drugs, while others
may transport a variety of chemically different compounds. These
proteins have been broadly classified into two groups: the ATP-binding
cassette (ABC) transporters (10, 28) and the secondary transporters (29). Drug efflux proteins in pathogens can
mediate resistance causing therapeutic failures.
Two multidrug transporters have been described in L. lactis.
The first (LmrA) is a member of the ABC superfamily (3);
the second (LmrP) is a proton-force-dependent transporter
(4). Both transporters confer resistance to ethidium
bromide, daunomycin, and tetraphenylphosphonium. Recent work shows
resistance to macrolides, lincosamides, and streptogramins and
tetracycline associated with LmrP expression (39).
Characterization of mef214 demonstrated that it mediated
multiple drug resistance; hence, it has been renamed mdt(A)
for multiple drug transporter. Mdt(A) is a plasmid-specified protein
which is unusual in that it is related to the major facilitator
superfamily (MFS) and yet contains two motifs C highly conserved in
antiporters (41) and a putative ATP-binding site. The
mdt(A) gene was cloned and studied for phenotype and function.
 |
MATERIALS AND METHODS |
Bacterial strains, growth conditions, and plasmids.
L. lactis subsp. lactis K214 bearing plasmid
pK214 (30), L. lactis subsp.
cremoris MG1363 (12) and LM0230
(9) were grown in M17 broth (Oxoid, Inc., New York, N.Y.)
supplemented with 0.5% (vol/vol) glucose (GM17) at 30°C.
Enterococcus faecalis JH2-2 (16) and
Staphylococcus aureus RN4220 (19) strains were grown in brain heart infusion (BHI) broth (Oxoid) at 37°C.
Escherichia coli strains DH5
(Life Technologies,
Gaithersburg, Md.), AG100 (13), AG100A (
acr)
(27), and transformants were grown in Luria-Bertani (LB)
broth at 37°C. Plasmid pUC19 (Life Technologies) and the shuttle
vector pWM401 (43) were used as cloning vectors. Plasmids
pK214 (30), pWM401, and pWVP6 were maintained in the strains by adding 20 µg/m of chloramphenicol per ml to the cultures, whereas the pUC vectors were maintained with 60 µg of ampicillin per
ml. Solid media were prepared by the addition of 1.2% (wt/vol) agar
(Oxoid) to broth.
Plasmid construction and transformation.
The
mdt(A)-containing region from plasmid pK214 was amplified by
PCR and cloned into vector pUC19 resulting in plasmid pUVP6. To allow
transformation and expression of mdt(A) in both
gram-negative and gram-positive bacteria, mdt(A) was
additionally isolated from pUVP6 with XbaI and
SphI restriction enzymes and inserted into the TetC
determinant of the shuttle vector pWM401. This new plasmid, pWVP6, as
well as the vector pWM401, was transformed into E. coli DH5
and AG100A by heat shock and into E. faecalis JH2-2,
S. aureus RN4220, and L. lactis MG1363 and LM0230
by electrotransformation. Plasmids were transformed into L. lactis, E. faecalis, and S. aureus cells by
electroporation in the Gene Pulser apparatus with the Pulse Controler
(Bio-Rad Laboratories) as described previously (11, 17,
34). E. faecalis and S. aureus
transformants were selected on BHI agar plates and
Lactococcus transformants were selected on GM17 agar plates,
each containing 10 µg of chloramphenicol per ml. E. coli
cells were transformed by heat shock treatment (33).
Antibiotic susceptibility tests.
The MIC was determined with
E-test strips (a gift of AB Biodisk, Solna, Sweden). The antimicrobial
agents tested were azithromycin, clarithromycin, erythromycin,
clindamycin, tetracycline, doxycycline, minocycline, nalidixic
acid, ciprofloxacin, clinafloxacin, fleroxacin, norfloxacin,
pefloxacin, sparfloxacin, quinupristin-dalfopristin, streptomycin,
gentamicin, kanamycin, benzylpenicillin, piperacillin, amoxillin-clavulanic acid, imipenem, oxacillin, chloramphenicol, fusidic acid, ceftriaxone, cefepime, cefotaxime, cefoxitin,
ceftizoxime, cephalothin, bacitracin, and rifampin. The MICs of
lincomycin and spiramycin were determined by microdilution test
according to NCCLS guidelines (25).
DNA techniques.
Plasmids were isolated from
Lactococcus, Enterococcus, and Staphylococcus
strains by the procedure of Anderson and McKay (2) by
adding 10 µg of lysostaphin per ml to the lysozyme solution for the
lysis of staphylococci. E. coli plasmids were isolated with
Qiagen Miniprep Kit (Qiagen, Inc., Valencia, Calif.). Restriction enzyme digestions were performed according to the suppliers'
directions. DNA was analyzed in 0.8% (wt/vol) agarose gels in TAE
buffer (33). mdt(A) was amplified by PCR from
plasmid pK214 (GenBank accession no. X92946) using Taq DNA
polymerase in accordance with the manufacturer's protocol (Life
Technologies). A ClaI restriction enzyme site was
incorporated into both forward (mdt1,
5'-GATGATATCGATGACAATGCAATGATGG [positions 10163 to 10180 in pK214]) and reverse (mdt1R, 5'-TTCCAGATCGATATCAAACTGACTGTG [positions 12058 to 12041]) primers to facilitate cloning into pUC19. Prior to the ligations (33), the digested PCR
product, DNA fragments, and the cloning vectors were purified from the agarose gel with the Qiaex II Gel Extraction Kit (Qiagen). Sequencing was performed at the Tufts University Core Facility using a 373 stretch
DNA sequencer (Applied Biosystems).
Drug efflux by starved-cell assay.
Bacterial cells (5 ml)
were grown to an A600 of 0.4, washed once in 0.1 M HEPES (pH 7.0) supplemented with 0.9% (wt/vol) NaCl, and resuspended
in the same buffer to obtain a final A600 of
1.0. E. coli cells were starved for at least 2 h at
37°C. Lactococcus cells were starved at 30°C overnight.
The starved cells were centrifuged and resuspended in
HEPES- sodium salt at A600 of 1.0 and
incubated at 30°C. For tetracycline assays, radiolabeled tetracycline
(0.2 µg of [3H]tetracycline per ml [specific activity,
0.81 Ci/mmol]; Dupont/NEN Research Products, Boston, Mass.) was added.
After 10 min, the cell suspension was divided into two halves, and
0.4% (vol/vol) glucose was added to one-half to energize the cells.
Then, 100- µl samples were taken at different times, resuspended in 6 ml of a saline solution (0.9% [wt/vol] NaCl solution containing 1 µg of tetracycline per ml). The samples were filtered through 0.45- µm-pore-size Gelman GN6 Metricel membrane filters prewet with the
saline solution. The filters were washed twice with 10 ml of saline
solution. Filters were air dried, and the radioactivity was assayed in
a scintillation counter. Each strain was tested in triplicate.
For the assay of erythromycin efflux, the procedure was performed as
described above with the following modifications. Bacterial cells (100 ml) were grown to an A600 of 0.7, washed once,
and starved overnight in 0.1 M HEPES supplemented with 0.9% (wt/vol) NaCl. The starved cells were resuspended in HEPES-sodium salt at an
A600 of 2.0, and
[N-methyl-14C]erythromycin (0.2 µg/ml;
specific activity, 54 mCi/mmol; Dupont/NEN Research Products) was
added. After a 5-min incubation, 0.4% (vol/vol) glucose was added, and
1-ml samples were directly filtered and washed with 0.9% (wt/vol) NaCl
containing 1 µg of erythromycin per ml.
Drug efflux by actively growing cells.
Efflux assays were
performed as described previously (45) with the following
minor modifications: the cells were grown in Mueller-Hinton broth
without antibiotics to an A600 of 0.4; the cultures were incubated with 100 µM CCCP (carbonyl cyanide
m-chlorophenylhydrazone), 20 mM arsenate, or 20 mM cyanide,
where appropriate, for 10 min before the addition of 0.2 µg of
[N-methyl-14C]erythromycin or 0.4 µg of
[3H]tetracycline per ml.
 |
RESULTS |
Mdt(A) protein.
The mdt(A) gene, 1,257 bp
in length (positions 10534 to 11790 in pK214; GenBank accession no.
X92946), specifies a putative 418-amino-acid protein with a calculated
molecular mass of 45.6 kDa (Fig. 1). A
putative ribosome-binding site capable of base pairing with the 3' end
of L. lactis 16S rRNA (UCUUUCCUCCA)
(5) starts six nucleotides upstream of the ATG
initiation codon. The promoter region of mdt(A) corresponds
to the conserved sequence consensus of lactococcal promoters
(8). Putative
10 and
35 promoter sequences exist at
nucleotides 10449 and 10426, respectively. The two hexamers are
separated by a 17-bp sequence, a TG dinucleotide is present at position
15, and an AT-rich region precedes the
35 sequence (Fig. 1).

View larger version (81K):
[in this window]
[in a new window]
|
FIG. 1.
Nucleotide and deduced amino acid sequence of
mdt(A) and the flanking regions. Putative ribosomal binding
site (RBS), promoter elements ( 10 and 35) and 12-TMS (boxes), which
were identified by the TopPred II program (7), are
indicated. Motifs A, B, C, G, and H correspond to the motifs described
previously (29) and are shown in boldface, as is the
putative ATP and GTP binding site. The position numbers of the
nucleotide sequence are indicated according to the complete nucleotide
sequence from pK214 (GenBank accession no. X92946). The primers
sequences used for PCR amplification are underlined.
|
|
Hydropathy analysis (20) predicts a highly hydrophobic
protein with 12 membrane-spanning regions and hydrophilic sequences at
both the N and the C termini of the protein. Motifs conserved among the
members of the 12- and 14-transmembrane segment (TMS) family of the MFS
(29) were localized in Mdt(A). Motif A has been located in
the putative cytoplasmic loop between TMSs 2 and 3; motif B was located
within TMS 4. Two motifs C were found in the Mdt(A) protein: the first
within TMS 5, as described for other proteins of the 12- and 14-TMS
family, and the second within TMS 9. Motif C is a part of the
antiporter motif (gX3GPXiGGxl) which is highly conserved in
the fifth membrane-spanning domain of the antiporters but which is
absent in the symporters and uniporters (14, 41). A motif
H, previously identified in the 14-TMS family proteins only, was
situated on the C-terminal side of each motif C: one in TMS 6 and one
in TMS 10. Motif G, conserved only in the 12-TMS family proteins, has
been identified in TMS 11.
An ATP-binding motif A (Walker A) (42) corresponding to
the highly conserved residues [AG]X4GK[ST] of the ABC
transporters spanned the junction of TMS 8 and the subsequent loop.
There were no identifiable Walker B motifs in the protein sequence.
Similarity searches of protein data banks using BLAST (National Center
for Biotechnology Information) and LALIGN (15) programs
revealed a paucity of close homology. There was a 32.9% identity
overall to Mef(A) from Streptococcus pyogenes
(6) and 32.1% identity to Mef(E) from Streptococcus
pneumoniae (36). The highest amino acid identity of
Mdt(A) with Mef(A) was identified in the first two TMSs of the
- and
-domains (44% with TMSs 1 and 2 and 41% with TMSs 7 and 8). The
other TMSs (TMSs 3 to 6 and TMSs 9 to 12) and the cytoplasmic loop of
Mdt(A) shared only 27 to 29% identity with Mef(A). Additionally,
Mef(A) did not harbor any ATP-binding site motif. Mdt(A) had less than
26% identity with the other known transmembrane proteins. The identity
of Mdt(A) with the lactococcal multidrug transporters was 18.8% for
LmrP (4) and 16.5% for LmrA (40).
Phenotypic expression of mdt(A).
The
mdt(A) gene specified drug resistance in L. lactis and in E. coli (Table
1) but not in E. faecalis and
S. aureus (data not shown). The most prominent phenotypic
expression was observed when the mdt(A) gene was placed into
the acrAB-deleted E. coli strain AG100A. Here,
Mdt(A) conferred increased resistance to the 14-membered macrolides
erythromycin and clarithromycin, to a 15-membered azithromycin, to a
16-membered spiramycin, to lincosamides clindamycin and lincomycin,
and to the streptogramin combination quinupristin and dalfopristin. Of
note was the increased level of resistance to the tetracyclines, i.e.,
tetracycline, doxycycline, and minocycline (Table 1). In E. coli DH5
, resistance to the macrolides and clindamycin was also
detected, but no conclusion could be drawn for lincomycin or the
streptogramin antibiotics; the MICs of these antibiotics for
E. coli DH5
were higher than the highest MIC tested.
A 20-fold increased resistance to tetracycline was noted, but little
change was observed in doxycycline and minocycline susceptibility.
View this table:
[in this window]
[in a new window]
|
TABLE 1.
Susceptibility of E. coli and L. lactis strains to macrolides, lincosamides, streptogramins,
and tetracyclines as determined by the E-test
|
|
In L. lactis, the gene mediated a greatly increased
resistance to the 14-membered macrolide erythromycin, but much
less so to clarithromycin. Resistance to a 15-membered
azithromycin was found, with a lower but reproducible twofold-increased
MIC of a 16-membered spiramycin, as well as of the streptogramin
combination quinupristin and dalfopristin. An increased MIC of
lincomycin, but not of clindamycin, was observed. As noted for
E. coli DH5
, Mdt(A)-mediated resistance (10-fold) to
tetracycline in L. lactis, but resulted in only 1.5- to
3-fold-increased resistance to doxycycline and minocycline (Table 1).
Drug accumulation assays.
Actively growing cells were used to
determine the amount of [3H]tetracycline and
[14C]erythromycin accumulated in L. lactis
MG1363 and MG1363/pWVP6 and in E. coli AG100A and
AG100A/pWVP6. The use of the acrAB-deleted AG100A allowed
measurement of the effective amount of antibiotics extruded by Mdt(A),
since acrAB is responsible for endogenous tetracycline and
erythromycin efflux in E. coli (26, 27).
Both E. coli and L. lactis strains expressing the
mdt(A) gene accumulated less tetracycline and erythromycin
than the wild-type hosts (data not shown). To examine the energy
dependence of the decreased level of antibiotic accumulated, E. coli cells were first starved for 2 h and L. lactis cells were starved overnight, and then the cells were
divided into two samples: one was given glucose either 5 or 10 minutes
after the addition of a radiolabeled drug.
[14C]erythromycin accumulated in both E. coli
and L. lactis strains (Fig. 2A and
B). A small, but detectable
energy-dependent decrease (10%) in [14C]erythromycin
accumulation could be detected in the wild-type L. lactis
strain MG1363 after the addition of glucose (Fig. 2A). In contrast, an
easily detected decreased [14C]erythromycin accumulation
was noted for the mdt(A)-expressing L. lactis
strain carrying pWVP6, which accumulated 50% less
[14C]erythromycin than the nonenergized cells after 20 min (Fig. 2A).

View larger version (20K):
[in this window]
[in a new window]
|
FIG. 2.
Accumulation of
[N-methyl-14C]erythromycin and
[3H]tetracycline in L. lactis (A and C) and
E. coli (B and D). The closed symbols represent the starved
cells and the open symbols indicate cells energized with 0.4% glucose
at 5 min for erythromycin and at 10 min for tetracycline (arrows) for
the wild-type strains (diamonds), and for the strains carrying pWVP6
with mdt(A) (triangles). The results are representative of
experiments performed in triplicate.
|
|
The starved E. coli AG100A and AG100A/pWVP6 cells showed
similar levels of erythromycin accumulation; however, after the
addition of glucose, the mdt(A)-carrying AG100A/pWVP6 cells
accumulated reproducibly less radiolabeled drug than the starved cells
AG100A/pWVP6 or AG100A (Fig. 2B).
The [3H]tetracycline accumulation assay (Fig. 2C and D)
showed no difference between starved or glucose-treated wild-type
L. lactis MG1363 cells. Starved MG1363/pWVP6 showed active
efflux of the accumulated drug following the addition of glucose (Fig. 2C). In the susceptible strain E. coli AG100A, the addition
of glucose to the starved cells stimulated the uptake of tetracycline due to the active tetracycline uptake known in E. coli
strains (23). The opposite phenomenon, i.e., reduced
[3H]tetracycline accumulation, occurred when glucose was
added to the starved AG100A/pWVP6 cells containing mdt(A)
(Fig. 2D).
In other experiments, we noted that the presence or absence of 100 µM
CCCP, 20 mM arsenate, or 20 mM cyanide had no effect on the
accumulation of [14C]erythromycin in L. lactis
MG1363, nor did these inhibitors affect [14C]erythromycin
accumulation in mdt(A)-expressing L. lactis
MG1363/pWVP6. A similar absence of effect of these inhibitors was seen
in E. coli strains harboring mdt(A) (data not shown).
 |
DISCUSSION |
The amino acid sequence analysis of Mdt(A), specified by the 30-kb
multiple antibiotic resistance plasmid pK214 from L. lactis, revealed a new type of protein with 12 putative transmembrane-spanning domains bearing the motifs A, B, C, G, and H that are conserved in the
efflux proteins of the MFS. Of distinction, Mdt(A) also possesses two
antiporter motifs (motif C) distributed among the
- and
-domains
(TMS 5 and TMS 9). The duplication of these motifs could ensue from an
evolutionary duplication forming the two domains, like that described
for TetA (32). Additionally, at the end of a helix in the
-domain, the Mdt(A) protein also contains an ATP-binding motif as
described for ABC transporters (10). Considering the small
number of residues that denote this motif, it may have no ATP-binding
properties. Further experiments are necessary to elucidate whether
Mdt(A) binds to ATP.
Mdt(A) shared 32.9% overall amino acid identity with Mef(A) from
S. pyogenes, with the highest identity scores in the two first TMSs (TMSs 1 and 2 and TMSs 6 and 7) of each
- or
-domain. There are no antiporter motifs in these segments that may increase the
level of identity. These TMSs might play an important role in the
export of macrolide antibiotics. However, Mdt(A) had a wider antibiotic
resistance spectrum than Mef(A), which only recognizes 14-membered and
15-membered macrolides. In E. coli AG100A, deleted of the
AcrAB pump, the Mdt(A) protein conferred resistance to 14-, 15-, and
16-membered macrolides, lincosamides, streptogramins, and tetracycline
antibiotics. Some differences in resistance profiles were seen among
other hosts. L. lactis harboring mdt(A) remained susceptible to clindamycin, whereas mdt(A)-carrying E. coli did not. Also, although plasmid pK214 replicated in E. faecalis JH2-2 and conferred resistances to tetracycline
[tet(S)], chloramphenicol (cat), and
streptomycin (str) (38), the mdt(A)
gene did not cause a detectable phenotype in this host, even after
induction attempts on gradient plates using different concentrations of erythromycin. The tet(S), cat, and str
genes are promiscuous genes that can be expressed in heterologous
gram-positive genera, e.g., Staphylococcus, Listeria,
Enterococcus, and Lactococcus. However, the
mdt(A) gene follows a lactococcal promoter which is known to
be functional in E. coli (18) but is more
stringently expressed in gram-positive bacteria.
The mechanism of resistance appears to be active efflux (Fig. 2);
however, the source of energy mediating efflux specified by Mdt(A)
remains unknown. The amino acid structure resembles a
proton-motive-force pump, but it also contains a putative ATP-binding site. While glucose addition following starvation caused efflux, protonophores known to destabilize the proton gradient across the
bacterial cell membrane had no effect on the Mdt(A) pump expressed in
E. coli or L. lactis. Efflux proteins that were
not affected by using CCCP or arsenate have been previously reported,
such as AcrD in E. coli (31), AmrAB-OprA in
Burkholderia pseudomallei (24), and Tap in
Mycobacterium fortuitum and Mycobacterium
tuberculosis (1).
The Mdt(A) protein offers a new look into the functioning of
energy-dependent efflux systems in bacteria, as well as antibiotic resistance mechanisms. Its structure is different from any antiporters previously described. Given its location on a plasmid in L. lactis, it is likely to be a resistance gene that was not selected
in medical environments but rather in animals. Resistant bacteria selected on food-producing animals may contaminate milk or meat and
persist in fermented food such as cheeses and sausages made with such
raw items. The increasing presence of resistances among pathogenic
bacteria, as well as commensals, should encourage a prudent and
appropriate use of antibiotics in both public health and agriculture.
 |
ACKNOWLEDGMENTS |
We thank L. L. McKay (University of Minnesota, Saint Paul)
and K. P. Scott (Rowett Research Institute, Aberdeen, United
Kingdom) for providing lactococcal strains LM0230 and MG1363, L. Wondrack and J. Sutcliffe (Pfizer, Inc., Groton, Conn.) for the kind
gift of radiolabeled erythromycin, and A. Bolmström (AB Biodisk,
Solna, Sweden) for the E-test strips.
This work was supported in part by grant 823A-053481 of the Swiss
National Science Foundation and USPHS grant NIH GM 51661.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Center for
Adaptation Genetics and Drug Resistance, Tufts University School of
Medicine, 136 Harrison Ave., Boston, MA 02111. Phone: (617) 636-6764. Fax: (617) 636-0458. E-mail: stuart.levy{at}tufts.edu.
 |
REFERENCES |
| 1.
|
Aínsa, J. A.,
M. C. J. Blokpoel,
I. Otal,
D. B. Young,
K. A. L. De Smet, and C. Martín.
1998.
Molecular cloning and characterization of Tap, a putative multidrug efflux pump present in Mycobacterium fortuitum and Mycobacterium tuberculosis.
J. Bacteriol.
180:5836-5843[Abstract/Free Full Text].
|
| 2.
|
Anderson, D. G., and L. L. McKay.
1983.
Simple and rapid method for isolating large plasmid DNA from lactic streptococci.
Appl. Environ. Microbiol.
46:549-552[Abstract/Free Full Text].
|
| 3.
|
Bolhuis, H.,
D. Molenaar,
G. Poelarends,
H. W. van Veen,
B. Poolman,
A. J. M. Driessen, and W. N. Konings.
1994.
Proton motive force-driven and ATP-dependent drug extrusion systems in multidrug-resistant Lactococcus lactis.
J. Bacteriol.
176:6957-6964[Abstract/Free Full Text].
|
| 4.
|
Bolhuis, H.,
G. Poelarends,
H. W. van Veen,
B. Poolman,
A. J. M. Driessen, and W. N. Konings.
1995.
The lactococcal lmrP gene encodes a proton motive force-dependent drug transporter.
J. Biol. Chem.
270:26092-26098[Abstract/Free Full Text].
|
| 5.
|
Chiaruttini, C., and M. Milet.
1993.
Gene organization, primary structure and RNA processing analysis of a ribosomal RNA operon in Lactococcus lactis.
J. Mol. Biol.
230:57-76[CrossRef][Medline].
|
| 6.
|
Clancy, J.,
J. Petitpas,
F. Dib-Hajj,
W. Yuan,
M. Cronan,
A. V. Kamath,
J. Bergeron, and J. A. Retsema.
1996.
Molecular cloning and functional analysis of a novel macrolide-resistance determinant, mefA, from Streptococcus pyogenes.
Mol. Microbiol.
22:867-879[CrossRef][Medline].
|
| 7.
|
Claros, M. G., and G. von Heijne.
1994.
TopPred II: an improved software for membrane protein structure predictions.
CABIOS
10:685-686[Free Full Text].
|
| 8.
|
de Vos, W. M.
1999.
Gene expression systems for lactic acid bacteria.
Curr. Opin. Microbiol.
2:289-295[CrossRef][Medline].
|
| 9.
|
Efstathiou, J. D., and L. L. McKay.
1977.
Inorganic salts resistance associated with a lactose-fermenting plasmid in Streptococcus lactis.
J. Bacteriol.
130:257-265[Abstract/Free Full Text].
|
| 10.
|
Fath, M. J., and R. Kolter.
1993.
ABC transporters: bacterial exporters.
Microbiol. Rev.
57:995-1017[Abstract/Free Full Text].
|
| 11.
|
Friesenegger, A.,
S. Fiedler,
L. A. Devriese, and R. Wirth.
1991.
Genetic transformation of various species of Enterococcus by electroporation.
FEMS Microbiol. Lett.
63:323-327[Medline].
|
| 12.
|
Gasson, M. J.
1983.
Plasmid complements of Streptococcus lactis NCDO 712 and other lactic streptococci after protoplast-induced curing.
J. Bacteriol.
154:1-9[Abstract/Free Full Text].
|
| 13.
|
George, A. M., and S. B. Levy.
1983.
Amplifiable resistance to tetracycline, chloramphenicol, and other antibiotics in Escherichia coli: involvement of a non-plasmid-determined efflux of tetracycline.
J. Bacteriol.
155:531-540[Abstract/Free Full Text].
|
| 14.
|
Ginn, S. L.,
M. H. Brown, and R. A. Skurray.
2000.
The TetA(K) tetracycline/H+ antiporter from Staphylococcus aureus: mutagenesis and functional analysis of motif C.
J. Bacteriol.
182:1492-1498[Abstract/Free Full Text].
|
| 15.
|
Huang, X., and W. Miller.
1991.
A time-efficient, linear-space local similarity algorithm.
Adv. Appl. Math.
12:337-357[CrossRef].
|
| 16.
|
Jacob, A. E., and S. J. Hobbs.
1974.
Conjugal transfer of plasmid-borne multiple antibiotic resistance in Streptococcus faecalis var. zymogenes.
J. Bacteriol.
117:360-372[Abstract/Free Full Text].
|
| 17.
|
Jahns, A.,
A. Schafer,
A. Geis, and M. Teuber.
1991.
Identification, cloning and sequencing of the replication region of Lactococcus lactis ssp. lactis biovar. diacetylactis Bu2 citrate plasmid pSL2.
FEMS Microbiol. Lett.
64:253-258[Medline].
|
| 18.
|
Jensen, P. R., and K. Hammer.
1998.
The sequence of spacers between the consensus sequences modulates the strength of prokaryotic promoters.
Appl. Environ. Microbiol.
64:82-87[Abstract/Free Full Text].
|
| 19.
|
Kreiswirth, B. N.,
S. Lofdahl,
M. J. Betley,
M. O'Reilly,
P. M. Schlievert,
M. S. Bergdoll, and R. P. Novick.
1983.
The toxic shock syndrome exotoxin structural gene is not detectably transmitted by a prophage.
Nature
305:709-712[CrossRef][Medline].
|
| 20.
|
Kyte, J., and R. F. Doolittle.
1982.
A simple method for displaying the hydropathic character of a protein.
J. Mol. Biol.
157:105-132[CrossRef][Medline].
|
| 21.
|
Lawrence, L. E., and J. F. Barrett.
1998.
Efflux pumps in bacteria: overview, clinical relevance, and potential pharmaceutical target.
Exp. Opin. Investig. Drugs
7:199-217.
|
| 22.
|
Levy, S. B.
1992.
Active efflux mechanisms for antimicrobial resistance.
Antimicrob. Agents Chemother.
36:695-703[Free Full Text].
|
| 23.
|
McMurry, L.,
R. E. Petrucci, Jr., and S. B. Levy.
1980.
Active efflux of tetracycline encoded by four genetically different tetracycline resistance determinants in Escherichia coli.
Proc. Natl. Acad. Sci. USA
77:3974-3977[Abstract/Free Full Text].
|
| 24.
|
Moore, R. A.,
D. DeShazer,
S. Reckseidler,
A. Weissman, and D. E. Woods.
1999.
Efflux-mediated aminoglycoside and macrolide resistance in Burkholderia pseudomallei.
Antimicrob. Agents Chemother.
43:465-470[Abstract/Free Full Text].
|
| 25.
|
National Committee for Clinical Laboratory Standards.
1997.
Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 4th ed., vol. 17.
, no. 2. Approved standard M7-A4. National Committee for Clinical Laboratory Standards, Wayne, Pa.
|
| 26.
|
Nikaido, H.
1996.
Multidrug efflux pumps of gram-negative bacteria.
J. Bacteriol.
178:5853-5859[Free Full Text].
|
| 27.
|
Okusu, H.,
D. Ma, and H. Nikaido.
1996.
AcrAB efflux pump plays a major role in the antibiotic resistance phenotype of Escherichia coli multiple antibiotic-resistance (Mar) mutants.
J. Bacteriol.
178:306-308[Abstract/Free Full Text].
|
| 28.
|
Ouellette, M.,
D. Légaré, and B. Papadopoulou.
1994.
Microbial multidrug-resistance ABC transporters.
Trends Microbiol.
2:407-411[CrossRef][Medline].
|
| 29.
|
Paulsen, I. T.,
M. H. Brown, and R. A. Skurray.
1996.
Proton-dependent multidrug efflux systems.
Microbiol. Rev.
60:575-608[Abstract/Free Full Text].
|
| 30.
|
Perreten, V.,
F. Schwarz,
L. Cresta,
M. Boeglin,
G. Dasen, and M. Teuber.
1997.
Antibiotic resistance spread in food.
Nature
389:801-802[Medline].
|
| 31.
|
Rosenberg, E. Y.,
D. Ma, and H. Nikaido.
2000.
AcrD of Escherichia coli is an aminoglycoside efflux pump.
J. Bacteriol.
182:1754-1756[Abstract/Free Full Text].
|
| 32.
|
Rubin, R. A.,
S. B. Levy,
R. L. Heinrikson, and F. J. Kezdy.
1990.
Gene duplication in the evolution of the two complementing domains of gram-negative bacterial tetracycline efflux proteins.
Gene
87:7-13[CrossRef][Medline].
|
| 33.
|
Sambrook, J.,
E. F. Fritsch, and T. Maniatis.
1989.
Molecular cloning: a laboratory manual, 2nd ed.
Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
|
| 34.
|
Schenk, S., and R. A. Laddaga.
1992.
Improved method for electroporation of Staphylococcus aureus.
FEMS Microbiol. Lett.
73:133-138[Medline].
|
| 35.
|
Sutcliffe, J.
1999.
Resistance to macrolides mediated by efflux mechanisms.
Curr. Opin. Anti-Infect. Investig. Drugs
1:403-412.
|
| 36.
|
Tait-Kamradt, A.,
J. Clancy,
M. Cronan,
F. Dib-Hajj,
L. Wondrack,
W. Yuan, and J. Sutcliffe.
1997.
mefE is necessary for the erythromycin-resistant M phenotype in Streptococcus pneumoniae.
Antimicrob. Agents Chemother.
41:2251-2255[Abstract].
|
| 37.
|
Teuber, M.
1995.
The genus Lactococcus, p. 173-234.
In
B. J. B. Wood, and W. H. Holzapfel (ed.), The genera of lactic acid bacteria. Blackie Academic & Professional, London, England.
|
| 38.
|
Teuber, M.,
L. Meile, and F. Schwarz.
1999.
Acquired antibiotic resistance in lactic acid bacteria from food.
Antonie Leeuwenhoek
76:115-137.
|
| 39.
|
van Veen, H. W.,
M. Putman,
A. Margolles,
K. Sakamoto, and W. N. Konings.
1999.
Structure-function analysis of multidrug transporters in Lactococcus lactis.
Biochim. Biophys. Acta
1461:201-206[Medline].
|
| 40.
|
van Veen, H. W.,
K. Venema,
H. Bolhuis,
I. Oussekno,
J. Kok,
B. Poolman,
A. J. M. Driessen, and W. N. Konings.
1996.
Multidrug resistance mediated by a bacterial homolog of the human multidrug transporter MDR1.
Proc. Natl. Acad. Sci. USA
93:10668-10672[Abstract/Free Full Text].
|
| 41.
|
Varela, M. F.,
C. E. Sansom, and J. K. Griffith.
1995.
Mutational analysis and molecular modelling of an amino acid sequence motif conserved in antiporters but not symporters in a transporter superfamily.
Mol. Membr. Biol.
12:313-319[Medline].
|
| 42.
|
Walker, J. E.,
M. Sarste,
M. J. Runswick, and N. J. Gay.
1982.
Distantly related sequences in the - and -subunits of ATP synthase, myosin, kinases and other ATP-requiring enzymes and a common nucleotide binding fold.
EMBO J.
1:945-951[Medline].
|
| 43.
|
Wirth, R.,
F. An, and D. B. Clewell.
1987.
Highly efficient cloning system for Streptococcus faecalis: protoplast transformation, shuttle vectors, and applications, p. 25-27.
In
J. J. Ferretti, and R. Curtiss III (ed.), Streptococcal genetics. American Society for Microbiology, Washington, D.C.
|
| 44.
|
Witte, W.
1998.
Medical consequences of antibiotic use in agriculture.
Science
279:996-997[Free Full Text].
|
| 45.
|
Wondrack, L.,
M. Massa,
B. V. Yang, and J. Sutcliffe.
1996.
Clinical strain of Staphylococcus inactivates and causes efflux of macrolides.
Antimicrob. Agents Chemother.
40:992-998[Abstract].
|
Antimicrobial Agents and Chemotherapy, April 2001, p. 1109-1114, Vol. 45, No. 4
0066-4804/01/$04.00+0 DOI: 10.1128/AAC.45.4.1109-1114.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Tanous, C., Chambellon, E., Yvon, M.
(2007). Sequence analysis of the mobilizable lactococcal plasmid pGdh442 encoding glutamate dehydrogenase activity. Microbiology
153: 1664-1675
[Abstract]
[Full Text]
-
Chen, Y.-G., Qu, T.-T., Yu, Y.-S., Zhou, J.-Y., Li, L.-J.
(2006). Insertion sequence ISEcp1-like element connected with a novel aph(2'') allele [aph(2'')-Ie] conferring high-level gentamicin resistance and a novel streptomycin adenylyltransferase gene in Enterococcus.. J Med Microbiol
55: 1521-1525
[Abstract]
[Full Text]
-
Perreten, V., Vorlet-Fawer, L., Slickers, P., Ehricht, R., Kuhnert, P., Frey, J.
(2005). Microarray-Based Detection of 90 Antibiotic Resistance Genes of Gram-Positive Bacteria. J. Clin. Microbiol.
43: 2291-2302
[Abstract]
[Full Text]
-
Kwon, D. H., Dore, M. P., Kim, J. J., Kato, M., Lee, M., Wu, J. Y., Graham, D. Y.
(2003). High-Level {beta}-Lactam Resistance Associated with Acquired Multidrug Resistance in Helicobacter pylori. Antimicrob. Agents Chemother.
47: 2169-2178
[Abstract]
[Full Text]
-
Raherison, S., Gonzalez, P., Renaudin, H., Charron, A., Bebear, C., Bebear, C. M.
(2002). Evidence of Active Efflux in Resistance to Ciprofloxacin and to Ethidium Bromide by Mycoplasma hominis. Antimicrob. Agents Chemother.
46: 672-679
[Abstract]
[Full Text]